Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study
The Journal of Clinical Endocrinology & Metabolism · 12.11.2026
DOI: 10.1210/clinem/dgag434 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.11.2026. Verfasst von Xiao Zhai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Peking Union Medical College Hospital, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Pek….
Abstract (Originalsprache)
Background
Glucocorticoid (GC) therapy is the cornerstone therapy for primary autoimmune hypophysitis (PAH), yet treatment failure and relapse are common. The concept and optimal management of "refractory" PAH remain undefined.
Objective
To define the clinical entity of refractory PAH, identify its distinguishing features, develop an exploratory screening model, and propose a structured management pathway based on treatment outcomes.
Methods
A retrospective cohort study of 100 PAH patients was conducted. Refractory PAH was defined as primary GC resistance or recurrence during tapering (GC-dependent). Twenty-two patients met these criteria. Baseline characteristics were compared between groups, and a exploratory screening model developed.
Results
Among 100 patients with hypophysitis, 22 (22%) met the criteria for refractory disease, including 19 with GC-dependent and 3 with GC-resistant hypophysitis. Compared with the non-refractory group, GC-dependent refractory hypophysitis was characterized by a lower prevalence of pregnancy-associated hypophysitis (5.9% vs. 41.7%, p=0.006), higher serum prolactin levels (median 30.2 ng/mL vs. 17.8 ng/mL, p=0.021), a higher prevalence of hypogonadotropic hypogonadism (82.4% vs. 55.4%, p=0.040), and a larger median pituitary stalk diameter (5.5 mm vs. 3.7 mm, p=0.043). No significant differences were observed between the GC-resistant group and the non-refractory group. Combination therapy with immunosuppressive agents (e.g., mycophenolate mofetil) or rituximab was effective in achieving radiological control. Glucocorticoid-related adverse events occurred in 40.9% of patients, most commonly hyperlipidemia and hyperglycemia.
Conclusion
This study defines and characterizes refractory PAH. The distinct clinical characteristics and the proposed structured diagnostic-therapeutic pathway offer a framework for managing this challenging condition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking Union Medical College Hospital, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, Beijing, CN.
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
ORCID-Profile: Xiao Zhai, Linjie Wang, Yong Yao, Hongbo Yang, Huijuan Zhu
Zitieren
APA
Zhai, X., Xu, Z., Xu, T., Zhang, Y., Duan, L., Wang, L., Yao, Y., Xing, B., Deng, K., Feng, F., Liang, Z., You, H., Yang, H., Pan, H., & Zhu, H. (2026). Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag434
Vancouver
Zhai X, Xu Z, Xu T, Zhang Y, Duan L, Wang L, et al. Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag434
BibTeX
@article{Zhai2026,
author = {Zhai, Xiao and Xu, Zhuoran and Xu, Tian and Zhang, Yueyang and Duan, Lian and Wang, Linjie and Yao, Yong and Xing, Bing and Deng, Kan and Feng, Feng and Liang, Zhiyong and You, Hui and Yang, Hongbo and Pan, Hui and Zhu, Huijuan},
title = {Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag434}
}
EUVIMED